. Author manuscript; available in PMC: 2023 Jun 12.

Published in final edited form as: Front Biosci (Landmark Ed). 2022 Jan 5;27(1):5. doi: 10.31083/j.fbl2701005

Table 1.

The IC₅₀ of TAK-243 in ABCB1-overexpressing cells.

Treatment	IC_50 value ± SD^a (mM, Resistance fold^b)
Treatment	TAK-243	TAK-243+ VPM 5 mM
KB-3–1	0.163 ± 0.043 (1.00)	0.137 ± 0.045 (0.84)
KB-C2	6.096 ± 0.580 (37.45)^*	0.514 ± 0.228 (3.15)^*
SW620	0.070 ± 0.006 (1.00)	0.064 ± 0.015 (0.92)
SW620/Ad300	1.991 ± 0.225 (28.46)^*	0.065 ± 0.023 (0.93)
SW620-ABCB1ko	0.030 ± 0.002 (1.00)	0.036 ± 0.002 (1.19)
SW620/Ad300-ABCB1ko	0.035 ± 0.001 (1.14)	0.034 ± 0.002 (1.11)
HEK293/pcDNA3.1	0.042 ± 0.016 (1.00)	0.032 ± 0.006 (0.77)
HEK293/ABCB1	0.441 ± 0.130 (10.62)^*	0.079 ± 0.026 (1.88)

IC₅₀ values are represented as mean ± SD from three independent experiments.

Rf: Resistance fold was calculated by dividing the IC₅₀ values of TAK- 243 in drug-resistant cells by the IC₅₀ of TAK-243 in parental cells.

p < 0.05 versus the control.